WO1993005807A3 - Agents activateurs des effets de l'erythropoietine et procedes d'utilisation desdits agents - Google Patents

Agents activateurs des effets de l'erythropoietine et procedes d'utilisation desdits agents Download PDF

Info

Publication number
WO1993005807A3
WO1993005807A3 PCT/US1992/007737 US9207737W WO9305807A3 WO 1993005807 A3 WO1993005807 A3 WO 1993005807A3 US 9207737 W US9207737 W US 9207737W WO 9305807 A3 WO9305807 A3 WO 9305807A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
erythropoietin
potentiating agents
disclosed
potentiating
Prior art date
Application number
PCT/US1992/007737
Other languages
English (en)
Other versions
WO1993005807A2 (fr
Inventor
Arthur J Sytkowski
Laurie Feldman
Original Assignee
New England Deaconess Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New England Deaconess Hospital filed Critical New England Deaconess Hospital
Priority to EP92920874A priority Critical patent/EP0603337A1/fr
Publication of WO1993005807A2 publication Critical patent/WO1993005807A2/fr
Publication of WO1993005807A3 publication Critical patent/WO1993005807A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C12N2500/62—DMSO
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/14—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Procédé destiné à augmenter l'effet de l'érythropoïétine en vue de la croissance et de la différenciation de cellules précurseurs de la lignée érythrocytaire. Des compositions pharmaceutiques utiles dans les procédés exposés sont également décrites.
PCT/US1992/007737 1991-09-13 1992-09-14 Agents activateurs des effets de l'erythropoietine et procedes d'utilisation desdits agents WO1993005807A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP92920874A EP0603337A1 (fr) 1991-09-13 1992-09-14 Agents activateurs des effets de l'erythropoietine et procedes d'utilisation desdits agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75940591A 1991-09-13 1991-09-13
US75948191A 1991-09-13 1991-09-13
US759,405 1991-09-13
US759,481 1991-09-13

Publications (2)

Publication Number Publication Date
WO1993005807A2 WO1993005807A2 (fr) 1993-04-01
WO1993005807A3 true WO1993005807A3 (fr) 1993-05-13

Family

ID=27116673

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/007737 WO1993005807A2 (fr) 1991-09-13 1992-09-14 Agents activateurs des effets de l'erythropoietine et procedes d'utilisation desdits agents

Country Status (3)

Country Link
EP (1) EP0603337A1 (fr)
AU (1) AU2677592A (fr)
WO (1) WO1993005807A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2301114A (en) * 1995-05-24 1996-11-27 Bradley Michael John Stringer Method for controlling differentiation of precursor cells
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
CN101495116A (zh) 2005-03-22 2009-07-29 哈佛大学校长及研究员协会 蛋白降解病症的治疗
WO2008091349A1 (fr) 2006-02-14 2008-07-31 The President And Fellows Of Harvard College Inhibiteurs bifonctionnels d'histone déacétylase
AU2007248656B2 (en) 2006-05-03 2013-04-04 Dana-Farber Cancer Institute, Inc. Histone deacetylase and tubulin deacetylase inhibitors
RU2515611C2 (ru) 2008-07-23 2014-05-20 Президент Энд Феллоуз Оф Гарвард Колледж Ингибиторы деацетилазы и их применение
WO2011019393A2 (fr) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Inhibiteurs de hdac classe- et isoforme-spécifiques et utilisations de ceux-ci

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004668A1 (fr) * 1987-11-13 1989-06-01 The Salk Institute For Biological Studies Potentialisation de l'erythropoiese

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004668A1 (fr) * 1987-11-13 1989-06-01 The Salk Institute For Biological Studies Potentialisation de l'erythropoiese

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BIOCHIMICA AND BIOPHYSICA ACTA vol. 605, 1980, HOLLAND pages 305 - 324 TROXLER D.H. ET AL 'The molecular biology of friend virus' cited in the application *
BLOOD vol. 73, no. 7, 15 May 1989, NEW YORK pages 1814 - 1820 FELDMAN L. ET AL 'B-lymphocyte derived erythroid burst-promoting activity is distinct from other known lymphokines' cited in the application *
CLINICAL RESEARCH vol. 38, no. 2, 1990, THOROFARE N.J. page 299A FELDMAN L. ET AL 'Human B-lymphocyte derived burst promoting activity (B-BPA) exerts discrete effects on the development of both BFU-E and CFU-E during erythropoiesis' *
JOURNAL OF CELL BIOLOGY vol. 111, no. 5(2), 1990, NEW YORK page 476A FELDMAN L. ET ALL 'Human B-lymphocyte derived burst promoting activity (B-BPA) stimulates the growth and differentiation of normal and transformed erythroid progenitors' *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA. vol. 84, no. 19, 1987, WASHINGTON US pages 6775 - 6779 FELDMAN L. ET AL 'Purification of a membranae -derived human erythroid growth factor' cited in the application *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA. vol. 88, no. 6, March 1991, WASHINGTON US pages 2535 - 2539 YONEKURA S. ET AL 'Erythropoietin receptors induced by dimethyl sulfoxide exhibit positive cooperativity associated with an amplified biologoc response' *

Also Published As

Publication number Publication date
EP0603337A1 (fr) 1994-06-29
WO1993005807A2 (fr) 1993-04-01
AU2677592A (en) 1993-04-27

Similar Documents

Publication Publication Date Title
TW289020B (fr)
HUS1400001I1 (hu) Kinazolin származékok, azok elõállítása, valamint a vegyületeket tartalmazó gyógyszerkészítmények
CA2180816A1 (fr) 6-dimethylaminomethyl-1-phenylcyclohexanes, principes actifs en pharmacie
CA2193337A1 (fr) Composes de type 1-phenyl-2-dimethylaminomethylcyclohexan-1-o1, ingredients pharmaceutiques actifs
AU6373094A (en) Enzyme-containing pharmaceutical or cosmetic composition, process for preparing the same and its use
AU7702291A (en) Dietary fiber, its process and physiologically active composition containing the same as an active ingredient
AU3091489A (en) Piperazine derivative or its salt, process for producing the same and pharmaceutical composition comprising the same as active ingredient
HUP9800138A3 (en) 8-substituted-1,3,8-triaza-spiro [4,5]-decan-4-on derivatives, process for producing them, pharmaceutical compositions containing the same and their use
CA2219818A1 (fr) Nouveaux derives de dolastatine, leur preparation et leur utilisation
AU6362796A (en) Substituted 4-phenylaminothiazoles, their process for preparation and the pharmaceutical compositions containing them
IL111533A0 (en) Quinoxalinedione derivatives, methods for the preparation thereof and pharmaceutical compositions containing the same
HUT63374A (en) Process for producing new benzoic acid derivatives having cardiovascular activity and pharmaceutical compositions comprising such active ingredient
HUP9601240A1 (en) Pyridin and pyrimidin derivatives, suitable as beta-adrenerg agonists, pharmaceutical compositions containing the same and their intermediates
AU8627898A (en) Pyrimidin-2,4,6-trion derivatives, method for producing the same and medicinal products containing these compounds
HUP9601176A3 (en) Amidine derivatives having adhesion-receptor antagonistic effect, pharmaceutical compositions containing the same and process for their preparation
HUT61554A (en) Process for producing 2,8-dioxabicyclo/3.2.1/octane derivatives and pharmaceutical compositions comprising same
AU1166895A (en) Polysubstituted 3-acylamino-5-phenyl-1,4-benzodiazepin-2-onederivatives, process for their preparation and the pharmaceutical compositions containing them
AU661017B2 (en) N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
HUP9901485A3 (en) Heterocyclylcarboxamide derivatives, pharmaceutical compositions containing the same, process for their preparation and their use
ZA934037B (en) Novel biologically active eburnamenine derivatives, pharmaceutical compositions containing them and process for preparing same.
WO1993005807A3 (fr) Agents activateurs des effets de l'erythropoietine et procedes d'utilisation desdits agents
AU4134297A (en) 2,4-disubstituted pyrimidine derivatives, process for producing the same, and medicinal compositions containing the same
AU8522491A (en) Substituted imidazoles, their preparation and pharmaceutical compositions
AU4845196A (en) 2-sulfinylnicotinamide derivatives, intermediate thereof, process for producing 2-sulfinylnicotinamide derivatives, and medicinal composition containing the same as active ingredient
WO2001046178A3 (fr) Pyrroles substitues

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1992920874

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1992920874

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1992920874

Country of ref document: EP